Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 | P35367 | 4/20 | 0.75 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.75 |
| ▸ | HTR2B | P41595 | 2/20 | 0.75 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.75 |
| ▸ | LMNA | P02545 | 2/20 | 0.75 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.75 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.75 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.75 |
| ▸ | HTR1A | P08908 | 1/20 | 0.75 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.75 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.75 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.75 |
| ▸ | DRD2 | P14416 | 1/20 | 0.75 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.75 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.75 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.75 |
| ▸ | DRD1 | P21728 | 1/20 | 0.75 |
| ▸ | DRD4 | P21917 | 1/20 | 0.75 |
| ▸ | DRD5 | P21918 | 1/20 | 0.75 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1695226 | 1.00 | HRH1 (0.75) | HRH1KCNH2HTR2BALDH1A1LMNA | |
| SCHEMBL2213039 | 1.00 | HRH1 (0.75) | HRH1KCNH2HTR2BALDH1A1LMNA | |
| SCHEMBL2738871 | 0.92 | HTR2B (0.77) | HRH1KCNH2HTR2BALDH1A1LMNA | |
| SCHEMBL10345076 | 0.88 | HTR2B (0.81) | HRH1KCNH2HTR2BALDH1A1LMNA | |
| SCHEMBL10344955 | 0.88 | HTR2B (0.81) | HRH1KCNH2HTR2BALDH1A1LMNA | |
| SCHEMBL10344954 | 0.88 | HTR2B (0.81) | HRH1KCNH2HTR2BALDH1A1LMNA | |
| Hydrochloric Acid SCHEMBL9133126 | 0.87 | HTR2B (0.79) | HRH1KCNH2HTR2BALDH1A1LMNA | |
| Hydrochloric Acid SCHEMBL9133130 | 0.87 | HTR2B (0.79) | HRH1KCNH2HTR2BALDH1A1LMNA | |
| SCHEMBL2615216 | 0.87 | HRH1 (0.77) | HRH1KCNH2HTR2BALDH1A1LMNA | |
| Doxepin SCHEMBL28075931 | 0.86 | HTR2B (0.95) | HRH1KCNH2HTR2BALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250268858-A1 | Methods Of Using Low-Dose Doxepin For The Improvement Of Sleep | CURRAX PHARMACEUTICALS LLC (US) | 2025-08-28 | — | — | US | disclosed |
| US-12083090-B2 | Methods of using low-dose doxepin for the improvement of sleep | CURRAX PHARMACEUTICALS LLC (US) | 2024-09-10 | — | — | US | disclosed |
| US-11007168-B2 | Doxepin trans isomers and isomeric mixtures and methods of using the same to treat sleep disorders | CURRAX PHARMACEUTICALS LLC (US) | 2021-05-18 | — | — | US | disclosed |
| US-20200345680-A1 | Methods Of Using Low-Dose Doxepin For The Improvement Of Sleep | CURRAX PHARMACEUTICALS LLC (US) | 2020-11-05 | — | — | US | disclosed |
| US-10758510-B2 | Doxepin isomers and isomeric mixtures and methods of using the same to treat sleep disorders | CURRAX PHARMACEUTICALS LLC (US) | 2020-09-01 | — | — | US | disclosed |
| US-10653662-B2 | Methods of using low-dose doxepin for the improvement of sleep | CURRAX PHARMACEUTICALS LLC (US) | 2020-05-19 | — | — | US | disclosed |
| US-20200101037-A1 | Doxepin Trans Isomers And Isomeric Mixtures And Methods Of Using The Same To Treat Sleep Disorders | WILMINGTON SAVINGS FUND SOCIETY, FSB | 2020-04-02 | — | — | US | disclosed |
| US-20190216766-A1 | Methods Of Using Low-Dose Doxepin For The Improvement Of Sleep | WILMINGTON SAVINGS FUND SOCIETY, FSB | 2019-07-18 | — | — | US | disclosed |
| US-20190099396-A1 | Doxepin Trans Isomers And Isomeric Mixtures And Methods Of Using The Same To Treat Sleep Disorders | WILMINGTON SAVINGS FUND SOCIETY, FSB | 2019-04-04 | — | — | US | disclosed |
| US-10238620-B2 | Methods of using low-dose doxepin for the improvement of sleep | PERNIX SLEEP, INC. (US) | 2019-03-26 | — | — | US | disclosed |
| US-8513299-B2 | Sleep efficiency | PERNIX SLEEP, INC. (US) | 2013-08-20 | — | — | US | disclosed |
| US-20130102658-A1 | DOXEPIN ISOMERS AND ISOMERIC MIXTURES AND METHODS OF USING THE SAME TO TREAT SLEEP DISORDERS | PROCOM ONE, INC. (US) | 2013-04-25 | — | — | US | disclosed |
| US-20130096188-A1 | DOXEPIN TRANS ISOMERS AND ISOMERIC MIXTURES AND METHODS OF USING THE SAME TO TREAT SLEEP DISORDERS | PROCOM ONE, INC. (US) | 2013-04-18 | — | — | US | disclosed |
| US-20120245222-A1 | METHODS OF USING LOW-DOSE DOXEPIN FOR THE IMPROVEMENT OF SLEEP | SOMAXON PHARMACEUTICALS, INC. (US) | 2012-09-27 | — | — | US | disclosed |
| US-20110178166-A1 | METHODS OF USING LOW-DOSE DOXEPIN FOR THE IMPROVEMENT OF SLEEP | SOMAXON PHARMACEUTICALS, INC. (US) | 2011-07-21 | — | — | US | disclosed |
| US-20100179215-A1 | DOXEPIN ISOMERS AND ISOMERIC MIXTURES AND METHODS OF USING THE SAME TO TREAT SLEEP DISORDERS | SOMAXON PHARMACEUTICALS, INC. (US) | 2010-07-15 | — | — | US | disclosed |
| US-20100179214-A1 | DOXEPIN TRANS ISOMERS AND ISOMERIC MIXTURES AND METHODS OF USING THE SAME TO TREAT SLEEP DISORDERS | SOMAXON PHARMACEUTICALS, INC. (US) | 2010-07-15 | — | — | US | disclosed |
| US-20090042971-A1 | METHOD OF USING LOW-DOSE DOXEPIN FOR THE IMPROVEMENT OF SLEEP | SOMAXON PHARMACEUTICALS, INC. (US) | 2009-02-12 | — | — | US | disclosed |
| US-20090042972-A1 | METHODS OF USING LOW-DOSE DOXEPIN FOR THE IMPROVEMENT OF SLEEP | SOMAXON PHARMACEUTICALS, INC. (US) | 2009-02-12 | — | — | US | disclosed |
| US-20070281990-A1 | Methods of using low-dose doxepin for the improvement of sleep | WILMINGTON SAVINGS FUND SOCIETY, FSB | 2007-12-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (19 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100179215-A1 | DOXEPIN ISOMERS AND ISOMERIC MIXTURES AND METHODS OF USING THE SAME TO TREAT SLEEP DISORDERS | CYP3A5, CYP2D6, CYP2C18 | HRH1 296/4885KCNH2 3264/4885HTR2B 251/4885 |
| US-20200101037-A1 | Doxepin Trans Isomers And Isomeric Mixtures And Methods Of Using The Same To Treat Sleep Disorders | CYP3A5, CYP21A2, CYP2D6 | HRH1 299/4885KCNH2 3272/4885HTR2B 270/4885 |
| US-20100179214-A1 | DOXEPIN TRANS ISOMERS AND ISOMERIC MIXTURES AND METHODS OF USING THE SAME TO TREAT SLEEP DISORDERS | CYP3A5, CYP21A2, CYP2D6 | HRH1 299/4885KCNH2 3272/4885HTR2B 270/4885 |
| US-20090042971-A1 | METHOD OF USING LOW-DOSE DOXEPIN FOR THE IMPROVEMENT OF SLEEP | BCHE, PER2, DPEP1 | HRH1 532/4885KCNH2 1963/4885HTR2B 697/4885 |
| US-20130102658-A1 | DOXEPIN ISOMERS AND ISOMERIC MIXTURES AND METHODS OF USING THE SAME TO TREAT SLEEP DISORDERS | CYP3A5, CYP2D6, CYP2C18 | HRH1 296/4885KCNH2 3264/4885HTR2B 251/4885 |
| US-12083090-B2 | Methods of using low-dose doxepin for the improvement of sleep | PER2, BCHE, MTNR1A | HRH1 436/4885KCNH2 2152/4885HTR2B 558/4885 |
| US-11007168-B2 | Doxepin trans isomers and isomeric mixtures and methods of using the same to treat sleep disorders | CYP3A5, CYP2D6, CYP21A2 | HRH1 328/4885KCNH2 3325/4885HTR2B 300/4885 |
| US-20130096188-A1 | DOXEPIN TRANS ISOMERS AND ISOMERIC MIXTURES AND METHODS OF USING THE SAME TO TREAT SLEEP DISORDERS | CYP3A5, CYP21A2, CYP2D6 | HRH1 299/4885KCNH2 3272/4885HTR2B 270/4885 |
| US-20090042972-A1 | METHODS OF USING LOW-DOSE DOXEPIN FOR THE IMPROVEMENT OF SLEEP | PER2, BCHE, MTNR1A | HRH1 436/4885KCNH2 2152/4885HTR2B 558/4885 |
| US-20190216766-A1 | Methods Of Using Low-Dose Doxepin For The Improvement Of Sleep | PER2, BCHE, MTNR1A | HRH1 436/4885KCNH2 2152/4885HTR2B 558/4885 |
| US-10758510-B2 | Doxepin isomers and isomeric mixtures and methods of using the same to treat sleep disorders | CYP3A5, CYP2D6, CYP2C18 | HRH1 296/4885KCNH2 3264/4885HTR2B 251/4885 |
| US-20250268858-A1 | Methods Of Using Low-Dose Doxepin For The Improvement Of Sleep | PER2, BCHE, MTNR1A | HRH1 436/4885KCNH2 2152/4885HTR2B 558/4885 |
| US-10238620-B2 | Methods of using low-dose doxepin for the improvement of sleep | PER2, BCHE, MTNR1A | HRH1 436/4885KCNH2 2152/4885HTR2B 558/4885 |
| US-10653662-B2 | Methods of using low-dose doxepin for the improvement of sleep | PER2, BCHE, MTNR1A | HRH1 436/4885KCNH2 2152/4885HTR2B 558/4885 |
| US-20190099396-A1 | Doxepin Trans Isomers And Isomeric Mixtures And Methods Of Using The Same To Treat Sleep Disorders | CYP3A5, CYP21A2, CYP2D6 | HRH1 299/4885KCNH2 3272/4885HTR2B 270/4885 |
| US-20120245222-A1 | METHODS OF USING LOW-DOSE DOXEPIN FOR THE IMPROVEMENT OF SLEEP | PER2, BCHE, MTNR1A | HRH1 436/4885KCNH2 2152/4885HTR2B 558/4885 |
| US-20110178166-A1 | METHODS OF USING LOW-DOSE DOXEPIN FOR THE IMPROVEMENT OF SLEEP | PER2, BCHE, MTNR1A | HRH1 436/4885KCNH2 2152/4885HTR2B 558/4885 |
| US-20200345680-A1 | Methods Of Using Low-Dose Doxepin For The Improvement Of Sleep | PER2, BCHE, MTNR1A | HRH1 436/4885KCNH2 2152/4885HTR2B 558/4885 |
| US-20070281990-A1 | Methods of using low-dose doxepin for the improvement of sleep | PER2, BCHE, MTNR1A | HRH1 436/4885KCNH2 2152/4885HTR2B 558/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.